1394165-41-3

Upstream product

• 58113-30-7 4-(3-chloropropoxy)-3-methoxyacetophenone 
• 1479-24-9 ethyl 2-fluorobenzoylacetate 
• 223679-79-6 5-(2-fluorobenzoyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 1436418-00-6 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinoline 
• 861881-05-2 4-chloro-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinoline 
• 960299-69-8 3-fluoro-4-((6-methoxy-7-(3-(piperdine-1-yl)propoxy)quinolin-4-yl)oxy)aniline 
• 1436417-97-8 6-methyloxy-7-(4-(3-(piperidin-1-yl)propoxy))-4-quiolinol 
• 85119-02-4 C₁₇H₁₃Cl₂FN₂O₃ 
• 1394166-09-6 6-methyloxy-7-(4-(3-chloropropoxy))-4-4-hydroxyquinoline 
• 393-52-2 2-Fluorobenzoyl chloride 
• 445-29-4 o-fluoro-benzoic acid 
• 1394166-08-5 (Ε)-1-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-3-(dimethylamino)propyl-2-en-1-one 
• 1160707-44-7 1-[4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl]ethan-1-one 

Relevant academic research and scientific papers

QUINOLINE AND CINNOLINE COMPOUNDS AND USE THEREOF

The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Quinoline and cinnoline derivatives and their applications

The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors

A series of novel 4-(2-fluorophenoxy)quinoline derivatives containing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety were designed, synthesized and evaluated for their in vitro biological activities against c-Met kinase and six typical cancer cell lines (A549, H460, HT-29, MKN-45, U87MG and SMMC-7721). All the prepared compounds showed moderate to excellent antiproliferative activity, and the analysis of their structure-activity relationships indicated that 2-chloro or 2-trifluoromethyl substituted phenyl group on the 1-position of cinnoline ring was more favorable for antitumor activity. In this study, a promising compound 33, with a c-Met IC50 value of 0.59 nM, was identified as a multitargeted receptor tyrosine kinase inhibitor.